Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

Men generally have more severe COVID-19 cases and higher death rates than women due to biological differences.

Foxp3 is crucial for regulatory T cell function, and targeting these cells may help treat immune disorders.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Both mouse and rat models are effective for testing alopecia areata treatments.

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

The document concludes that inflammation markers can be used in diabetes, vitamin D3 affects immune pathways, hyperthyroidism changes hormone levels, androgen levels help diagnose Adrenocortical Carcinoma, erectile dysfunction is linked to diabetes, hypogonadism is common in HIV-infected males, and hormones can be biomarkers for various conditions.

Different types of sun exposure damage skin cells and immune cells, with chronic exposure leading to more severe and lasting damage.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

The Wnt/β-catenin pathway is important for body functions and diseases, and targeting it may treat conditions like cancer, but with safety challenges.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

RANK is a key target in breast cancer treatment due to its role in tumor growth and bone metastasis.

Ionizing radiation causes irreversible skin damage, with single doses leading to acute injury and hair graying, and fractional doses causing more severe long-term tissue damage.

Genetic factors affect hair loss, and molecular testing may help predict, diagnose, and treat it.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.

Scalp melanoma, a deadly skin cancer, is often found late due to its hard-to-see location, especially in older men. Early detection, possible treatments, and the role of hairdressers in spotting it early are discussed. More research is needed to improve detection and treatment.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Lymphatic vessels are essential for health and can be targeted to treat various diseases.

Discoid Lupus Erythematosus often causes scarring hair loss, is influenced by genetics and environment, and requires early treatment to prevent worsening.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.

Understanding how Regulatory T Cells work could help create treatments for certain skin diseases and cancers.

Understanding drug interactions, side effects, and patient-specific factors is crucial for effective dermatological care.

New cytokine-targeted therapies show promise for treating alopecia areata.